HomeAbout usProductsInvestor centreMedia centrePartneringCareers

Pipeline


Antisoma clinical development pipeline



Antisoma clinical development pipeline link to AS1411 page link to AS1402 page link to AS1409 page link to AS1413 page link to ASA404 page link to Oral fludarabine page

Oral fludarabine is a purine nucleoside analogue in registration for CLL

ASA404 is a Tumour-Vascular Disrupting Agent (Tumour-VDA) entering phase III in non-small cell lung cancer

AS1413 (amonafide malate) is a DNA intercalator in phase III in secondary AML

AS1411 is a DNA aptamer in phase II in acute myeloid leukaemia (AML) 

AS1402 is a humanised monoclonal antibody entering phase II in breast cancer

AS1409 is an antibody-cytokine fusion protein in phase I clinical studies in renal cell carcinoma and melanoma

P2045 is a synthetic peptide-based targeted radiopharmaceutical in phase I studies

Delivered by Investis and link to website (opens in a new window)